Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Acid-stable Protease Inhibitor
2. Miraclid
3. Mr 20
4. Mr 20 (magnetic Powder) Of Urinastatin
5. Mr-20 (magnetic Powder)
6. Trypsin Inhibitor Mr-20
7. Ulinastatin
8. Urinary Trypsin Inhibitor
9. Urinary Trypsin Inhibitor (68)
10. Urinary Trypsin Inhibitor-like Inhibitor (43)
11. Urinastatin
12. Uti(68)
13. Uti68
1. 80499-32-7
2. 80449-32-7
3. 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-8-ene
4. Trypsin Inhibitor (human Urine Urinastatin Protein Moiety)
5. 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene
6. 2,4-dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-
7. Trypsin Inhibitor Mr-20
8. Mr-20 (magnetic Powder)
9. Uti(68)
10. Acid-stable Protease Inhibitor
11. Urinary Trypsin Inhibitor (68)
12. Mr 20
13. Unii-or3s9if86u
14. Uristatin
15. Mingin
16. Urinary Trypsin Inhibitor-like Inhibitor (43)
17. Trypsin Inhibitor Uti
18. Ulinastatin [inn:jan]
19. Trypsin Inhibitor, Mingin
20. Trypsin Inhibitor, Bikunin
21. Urinary Trypsin Inhibitor 1
22. 3-(2-furanyl)-2,4-dioxaspiro(5.5)undec-8-ene
23. Dtxsid801001247
24. Bcp08067
25. Akos025401879
26. Ac-26827
27. Hy-21646
28. D77201
29. 9-(2-furyl)-8,10-dioxaspiro[5.5]undec-3-ene
| Molecular Weight | 220.26 g/mol |
|---|---|
| Molecular Formula | C13H16O3 |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 220.109944368 g/mol |
| Monoisotopic Mass | 220.109944368 g/mol |
| Topological Polar Surface Area | 31.6 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 266 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Trypsin Inhibitors
Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. (See all compounds classified as Trypsin Inhibitors.)
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Lead Product(s): Urinastatin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bharat Serums to assess sepsis drug Ulinastatin for Covid-19
Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Lead Product(s): Urinastatin,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : The First Affiliated Hospital of Guangzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2016

Details:
Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.
Lead Product(s): Urinastatin,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Techpool Bio-Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2016

Lead Product(s) : Urinastatin,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Techpool Bio-Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Defects, Congenital.
Lead Product(s): Urinastatin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Defects, Congenital.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pancreatitis.
Lead Product(s): Urinastatin,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Urinastatin,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin in Severe Acute Pancreatitis
Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pancreatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
11 Jul 2022
Reply
21 Feb 2022
Reply
07 Aug 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
21
PharmaCompass offers a list of Urinastatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Urinastatin manufacturer or Urinastatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Urinastatin manufacturer or Urinastatin supplier.
A Urinastatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Urinastatin, including repackagers and relabelers. The FDA regulates Urinastatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Urinastatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Urinastatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Urinastatin supplier is an individual or a company that provides Urinastatin active pharmaceutical ingredient (API) or Urinastatin finished formulations upon request. The Urinastatin suppliers may include Urinastatin API manufacturers, exporters, distributors and traders.
click here to find a list of Urinastatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Urinastatin Drug Master File in Korea (Urinastatin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Urinastatin. The MFDS reviews the Urinastatin KDMF as part of the drug registration process and uses the information provided in the Urinastatin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Urinastatin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Urinastatin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Urinastatin suppliers with KDMF on PharmaCompass.
A Urinastatin written confirmation (Urinastatin WC) is an official document issued by a regulatory agency to a Urinastatin manufacturer, verifying that the manufacturing facility of a Urinastatin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Urinastatin APIs or Urinastatin finished pharmaceutical products to another nation, regulatory agencies frequently require a Urinastatin WC (written confirmation) as part of the regulatory process.
click here to find a list of Urinastatin suppliers with Written Confirmation (WC) on PharmaCompass.
Urinastatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Urinastatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Urinastatin GMP manufacturer or Urinastatin GMP API supplier for your needs.
A Urinastatin CoA (Certificate of Analysis) is a formal document that attests to Urinastatin's compliance with Urinastatin specifications and serves as a tool for batch-level quality control.
Urinastatin CoA mostly includes findings from lab analyses of a specific batch. For each Urinastatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Urinastatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Urinastatin EP), Urinastatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Urinastatin USP).